Danazol for the treatment of idiopathic thrombocytopenic purpura

Yeon Ahn, W. J. Harrington, S. R. Simon, R. Mylvaganam, L. M. Pall, A. G. So

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Idiopathic thrombocytopenic purpura is an autoimmune disorder, most common in young women. We treated 22 patients with this disorder (12 of whom were women) with danazol, an androgen with reduced virilizing capability, for two months or longer. Fifteen had undergone splenectomy, all were receiving glucocorticoids, and 18 had also been given other treatments. Fifteen of the patients were benefited, 11 with sustained normalization of their platelet counts. Six of eight patients tested had initial increases in circulating platelet-reactive IgG; in all six there was a marked decrease concomitant with danazol therapy. Danazol was effective in both men and women, irrespective of previous treatments. The duration of remissions ranged from 2 to 13 months. The drug was well tolerated and appears to be better suited than glucocorticoids for long-term management of idiopathic thrombocytopenic purpura, but the exact indications for the use of danazol in this disorder remain to be determined.

Original languageEnglish
Pages (from-to)1396-1399
Number of pages4
JournalNew England Journal of Medicine
Volume308
Issue number23
StatePublished - Jul 21 1983

Fingerprint

Danazol
Idiopathic Thrombocytopenic Purpura
Glucocorticoids
Splenectomy
Therapeutics
Platelet Count
Androgens
Blood Platelets
Immunoglobulin G
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ahn, Y., Harrington, W. J., Simon, S. R., Mylvaganam, R., Pall, L. M., & So, A. G. (1983). Danazol for the treatment of idiopathic thrombocytopenic purpura. New England Journal of Medicine, 308(23), 1396-1399.

Danazol for the treatment of idiopathic thrombocytopenic purpura. / Ahn, Yeon; Harrington, W. J.; Simon, S. R.; Mylvaganam, R.; Pall, L. M.; So, A. G.

In: New England Journal of Medicine, Vol. 308, No. 23, 21.07.1983, p. 1396-1399.

Research output: Contribution to journalArticle

Ahn, Y, Harrington, WJ, Simon, SR, Mylvaganam, R, Pall, LM & So, AG 1983, 'Danazol for the treatment of idiopathic thrombocytopenic purpura', New England Journal of Medicine, vol. 308, no. 23, pp. 1396-1399.
Ahn Y, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. New England Journal of Medicine. 1983 Jul 21;308(23):1396-1399.
Ahn, Yeon ; Harrington, W. J. ; Simon, S. R. ; Mylvaganam, R. ; Pall, L. M. ; So, A. G. / Danazol for the treatment of idiopathic thrombocytopenic purpura. In: New England Journal of Medicine. 1983 ; Vol. 308, No. 23. pp. 1396-1399.
@article{3147ee8fd04442ebb93c45ab67b8c728,
title = "Danazol for the treatment of idiopathic thrombocytopenic purpura",
abstract = "Idiopathic thrombocytopenic purpura is an autoimmune disorder, most common in young women. We treated 22 patients with this disorder (12 of whom were women) with danazol, an androgen with reduced virilizing capability, for two months or longer. Fifteen had undergone splenectomy, all were receiving glucocorticoids, and 18 had also been given other treatments. Fifteen of the patients were benefited, 11 with sustained normalization of their platelet counts. Six of eight patients tested had initial increases in circulating platelet-reactive IgG; in all six there was a marked decrease concomitant with danazol therapy. Danazol was effective in both men and women, irrespective of previous treatments. The duration of remissions ranged from 2 to 13 months. The drug was well tolerated and appears to be better suited than glucocorticoids for long-term management of idiopathic thrombocytopenic purpura, but the exact indications for the use of danazol in this disorder remain to be determined.",
author = "Yeon Ahn and Harrington, {W. J.} and Simon, {S. R.} and R. Mylvaganam and Pall, {L. M.} and So, {A. G.}",
year = "1983",
month = "7",
day = "21",
language = "English",
volume = "308",
pages = "1396--1399",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

TY - JOUR

T1 - Danazol for the treatment of idiopathic thrombocytopenic purpura

AU - Ahn, Yeon

AU - Harrington, W. J.

AU - Simon, S. R.

AU - Mylvaganam, R.

AU - Pall, L. M.

AU - So, A. G.

PY - 1983/7/21

Y1 - 1983/7/21

N2 - Idiopathic thrombocytopenic purpura is an autoimmune disorder, most common in young women. We treated 22 patients with this disorder (12 of whom were women) with danazol, an androgen with reduced virilizing capability, for two months or longer. Fifteen had undergone splenectomy, all were receiving glucocorticoids, and 18 had also been given other treatments. Fifteen of the patients were benefited, 11 with sustained normalization of their platelet counts. Six of eight patients tested had initial increases in circulating platelet-reactive IgG; in all six there was a marked decrease concomitant with danazol therapy. Danazol was effective in both men and women, irrespective of previous treatments. The duration of remissions ranged from 2 to 13 months. The drug was well tolerated and appears to be better suited than glucocorticoids for long-term management of idiopathic thrombocytopenic purpura, but the exact indications for the use of danazol in this disorder remain to be determined.

AB - Idiopathic thrombocytopenic purpura is an autoimmune disorder, most common in young women. We treated 22 patients with this disorder (12 of whom were women) with danazol, an androgen with reduced virilizing capability, for two months or longer. Fifteen had undergone splenectomy, all were receiving glucocorticoids, and 18 had also been given other treatments. Fifteen of the patients were benefited, 11 with sustained normalization of their platelet counts. Six of eight patients tested had initial increases in circulating platelet-reactive IgG; in all six there was a marked decrease concomitant with danazol therapy. Danazol was effective in both men and women, irrespective of previous treatments. The duration of remissions ranged from 2 to 13 months. The drug was well tolerated and appears to be better suited than glucocorticoids for long-term management of idiopathic thrombocytopenic purpura, but the exact indications for the use of danazol in this disorder remain to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0020636872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020636872&partnerID=8YFLogxK

M3 - Article

C2 - 6682484

AN - SCOPUS:0020636872

VL - 308

SP - 1396

EP - 1399

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 23

ER -